comparing cardiovascular and kidney outcomes with tirzepatide vs. glp-1 agonists linked to lower risk for death, adverse CV GLP-1s Tirzepatide and Cardiovascular Outcomes: A

This is a announcement of a proposed order, and currently companies may continue to market OTC drug products containing phenylephrine until the final order is made

They are being evaluated with the wrong tools

Lipsky RH, Xu K, Zhu D, Kelly C, Terhakopian A, Novelli A, et al

Phase 2: Low-Intensity Shockwave Therapy (LIST) and PRP Preparation Following venipuncture and blood collection, biologic processing is initiated and typically requires more than 30 minutes

2025 Frontiers study: Restored mtDNA in aging cells, extending lifespan 15%

The conception, design, interpretation of the results, writing, review, and approval of the submitted manuscript were made by all authors